Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin - Full Text View

Purpose

The purpose of this study is to compare the tolerability of MetroGel® 1% to Finacea® 15% in subjects with healthy skin applied according to product labeling for three weeks.

Condition	Intervention	Phase
Skin Manifestations	Drug: metronidazole 1% gel Drug: azelaic acid 15% gel	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single Blind (Investigator) Primary Purpose: Treatment
Official Title:	Split-Face Tolerability Comparison Between MetroGel® (Metronidazole Gel) 1% vs Finacea® (Azelaic Acid) 15% in Subjects With Healthy Skin

Resource links provided by NLM:

Drug Information available for: Azelaic acid Metronidazole Metronidazole hydrochloride

U.S. FDA Resources

Further study details as provided by Galderma Laboratories, L.P.:

Primary Outcome Measures:

Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Scores in Each Assessment (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3 [ Time Frame: baseline to week 3 ]
Number of participants who were a success with regard to worst post-baseline tolerability scores in each of the tolerability assessments at any time point between baseline and week 3. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success was defined as a tolerability score of 0.

Secondary Outcome Measures:

Number of Participants Who Were a Success With Regard to Worst-baseline Tolerability Assessment Scores in Each Assessment (Erythema, Scaling, Dryness, Stinging/Burning) on Day 22 [ Time Frame: day 22 ]
Number of participants who were a success with regard to worst-baseline tolerability assessment scores for each assessment (erythema, scaling, dryness, stinging/burning) on day 22. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success was defined as a tolerability score of 0 for each assessment.
6 Question Subject Preference Survey at Week 3 [ Time Frame: 3 weeks ]
Number of participants per response to each question of the subject preference survey at week 3


Enrollment:	77
Study Start Date:	June 2010
Study Completion Date:	June 2010
Primary Completion Date:	June 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: metronidazole 1% gel	Drug: metronidazole 1% gel Apply topically once daily on one side of the face for three weeks Other Name: MetroGel® 1% gel
Active Comparator: azelaic acid 15% gel	Drug: azelaic acid 15% gel Apply topically twice daily on the opposite side of the face for three weeks Other Name: Finacea® 15% Gel

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Healthy male and female adults (ages 18 years or older)
Subjects with healthy skin as determined by the clinical grader

Exclusion Criteria:

Subjects with a degree of skin pigmentation that interferes with the reading of skin reactions
Subjects with known allergy to one of the components of the study drugs (refer to the package inserts for MetroGel® 1% and Finacea® Gel 15%)
Subjects who have participated in another investigational drug or device research study within 30 days of enrollment
Subjects with a washout period for topical treatment on the treated area less than 1 week for corticosteroids and/or 4 weeks for retinoids
Subjects with a washout period for systemic treatment less than 1 week for medications that may increase photosensitivity and/or 4 weeks for corticosteroids and/or 6 months for retinoids
Subjects with current sunburn, eczema, atopic dermatitis, perioral dermatitis, rosacea, or other topical conditions on the area to be treated
Subjects who foresee unprotected and intense UV exposure during the study (mountain sports, UV radiation, sunbathing, etc.)

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01139047

Locations


United States, Colorado
Thomas J. Stephens & Associates, Inc.
Colorado Springs, Colorado, United States, 80915

Sponsors and Collaborators

Galderma Laboratories, L.P.

Investigators


Study Director:	Ronald W Gottschalk, MD	Galderma Laboratories, L.P.

More Information


Responsible Party:	Galderma Laboratories, L.P.
ClinicalTrials.gov Identifier:	NCT01139047 History of Changes
Other Study ID Numbers:	US10160
Study First Received:	June 4, 2010
Results First Received:	June 28, 2011
Last Updated:	September 21, 2012

Additional relevant MeSH terms:


Skin Manifestations Signs and Symptoms Metronidazole Azelaic acid Anti-Infective Agents	Antiprotozoal Agents Antiparasitic Agents Antineoplastic Agents Dermatologic Agents

ClinicalTrials.gov processed this record on June 28, 2017